Dazodalibep kan lindra Sjögrens syndrom.

Published Date: 10 Jun 2023

In a two-stage, phase 2 clinical trial, the novel agent—which targets CD40 ligand—showed promising results, especially for patients with significant symptom burden but limited systemic organ involvement.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An ancient signaling pathway and 20 years of research offer hope for rare cancer

2.

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

3.

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

Prostate cancer detection with PET CT and PET MRI is comparable.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot